Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in hematological malignancies, yet its translation to solid tumors remains limited by heterogeneous and often low target antigen density. TCR-like (TCRL) based CARs, which recognize intracellular antigens presented by major histocompatibility complex (MHC) molecules, significantly expand the targetable landscape for solid tumors such as melanoma. In this study, we systematically investigated how the integration of distinct costimulatory domains (CD28 and 4-1BB) and primary activation elements (CD3ζ versus FcRγ) dictates the functional avidity outcome of TCRL CAR T-cells targeting the melanoma-associated Tyrosinase/HLA-A2 complex. Using a well-defined experimental system with controlled antigen densities, we profiled the phenotypic, cytolytic, and transcriptomic landscapes of multiple second- and third-generation CAR architectures. Our results demonstrate that CD28-based signaling lowers the antigen density threshold required for robust immediate cytotoxicity but renders the T-cells susceptible to rapid exhaustion upon chronic stimulation. In contrast, 4-1BB costimulation confers a distinct transcriptomic fingerprint that limits exhaustion, albeit requiring higher antigen density for optimal initial activation. Crucially, structural tuning of these modules led to the engineering of a novel hybrid CAR construct that integrates both CD3ζ and FcRγ activation domains in a position-dependent manner. This novel hybrid configuration exhibited synergistic signal amplification, overcoming the low-antigen-density barrier and demonstrating superior functional sensitivity in our in vitro models. Together, these exploratory findings elucidate the critical interplay between biophysical binding properties, costimulatory signaling, and primary activation elements, providing a strong rational framework for future in vivo evaluation of optimized TCRL-based CAR T-cell therapies.
No takes yet. Share an insight, caveat, or question.
Levin-Piaeda et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: